JP7649239B2 - キメラ抗原受容体ファクトリおよびその使用方法 - Google Patents

キメラ抗原受容体ファクトリおよびその使用方法 Download PDF

Info

Publication number
JP7649239B2
JP7649239B2 JP2021530875A JP2021530875A JP7649239B2 JP 7649239 B2 JP7649239 B2 JP 7649239B2 JP 2021530875 A JP2021530875 A JP 2021530875A JP 2021530875 A JP2021530875 A JP 2021530875A JP 7649239 B2 JP7649239 B2 JP 7649239B2
Authority
JP
Japan
Prior art keywords
amino acid
cdr1
cdr2
cdr3
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513668A (ja
JPWO2020113224A5 (https=
JP2022513668A5 (https=
Inventor
ウェイン エイ． マラスコ
クアン カレン チュー
ユーフェイ ワン
マシュー チャン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2022513668A publication Critical patent/JP2022513668A/ja
Publication of JPWO2020113224A5 publication Critical patent/JPWO2020113224A5/ja
Publication of JP2022513668A5 publication Critical patent/JP2022513668A5/ja
Priority to JP2024168470A priority Critical patent/JP2025011142A/ja
Application granted granted Critical
Publication of JP7649239B2 publication Critical patent/JP7649239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2021530875A 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法 Active JP7649239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168470A JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773885P 2018-11-30 2018-11-30
US62/773,885 2018-11-30
US201962826462P 2019-03-29 2019-03-29
US62/826,462 2019-03-29
PCT/US2019/064032 WO2020113224A2 (en) 2018-11-30 2019-12-02 Chimeric antigen receptor factories and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168470A Division JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Publications (4)

Publication Number Publication Date
JP2022513668A JP2022513668A (ja) 2022-02-09
JPWO2020113224A5 JPWO2020113224A5 (https=) 2023-04-14
JP2022513668A5 JP2022513668A5 (https=) 2023-04-14
JP7649239B2 true JP7649239B2 (ja) 2025-03-19

Family

ID=70853578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Country Status (7)

Country Link
US (1) US12577311B2 (https=)
EP (1) EP3887509A4 (https=)
JP (2) JP7649239B2 (https=)
KR (1) KR20210135475A (https=)
AU (1) AU2019387566A1 (https=)
CA (1) CA3119644A1 (https=)
WO (1) WO2020113224A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
US20220249640A1 (en) * 2019-06-14 2022-08-11 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
EP4226972A4 (en) * 2020-10-12 2025-01-01 Nanjing Iaso Biotechnology Co., Ltd. CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114565761B (zh) * 2022-02-25 2023-01-17 无锡市第二人民医院 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法
CA3250590A1 (en) * 2022-06-09 2023-12-14 Telix Pharmaceuticals (Innovations) Pty Ltd POLYTHERAPY
KR20250158048A (ko) * 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
WO2018152181A1 (en) 2017-02-14 2018-08-23 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
WO2018156802A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
KR20170093248A (ko) 2014-12-19 2017-08-14 다나-파버 캔서 인스티튜트 인크. 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
WO2018152181A1 (en) 2017-02-14 2018-08-23 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
WO2018156802A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer

Also Published As

Publication number Publication date
WO2020113224A3 (en) 2020-08-20
JP2022513668A (ja) 2022-02-09
KR20210135475A (ko) 2021-11-15
CA3119644A1 (en) 2020-06-04
EP3887509A4 (en) 2022-08-31
AU2019387566A1 (en) 2021-06-17
WO2020113224A2 (en) 2020-06-04
EP3887509A2 (en) 2021-10-06
JP2025011142A (ja) 2025-01-23
US12577311B2 (en) 2026-03-17
US20220047634A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7649239B2 (ja) キメラ抗原受容体ファクトリおよびその使用方法
AU2020204373B2 (en) Chimeric antigen receptors and methods of use thereof
US20240166755A1 (en) Chimeric antigen receptors targeting cancer
CN113784732B (zh) 靶向bcma的工程化免疫细胞及其用途
EP3286225B1 (en) Cd5 chimeric antigen receptor for adoptive t cell therapy
CN108884164B (zh) 用于免疫疗法的经修饰细胞
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
US20250296975A1 (en) Engineered cells, t cell immune modulating antibodies and methods for using the same
WO2017219934A1 (zh) 一种高效稳定表达抗体的杀伤性细胞及其用途
KR20170093248A (ko) 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법
WO2020167957A1 (en) High affinity engineered t-cell receptors targeting cmv infected cells
CN109897114B (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
JP2025508041A (ja) 遺伝子操作されたｂ細胞及びその使用方法
WO2023025779A1 (en) Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
EP4392058A1 (en) Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
HK40026612A (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250307

R150 Certificate of patent or registration of utility model

Ref document number: 7649239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150